Drug Trial Radar · NCT07639879
TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Jul 30, 2029
Study completion Jul 30, 2030
Sponsor
- Lead sponsor
- Tarapeutics Science Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multicenter Phase III study evaluating the efficacy and safety of TR115, an EZH2 inhibitor, versus investigator's choice (chidamide, golidocitinib, mitoxantrone liposome, or gemcitabine) in patients with relapsed and/or refractory peripheral T/NK-cell lymphoma. Approximately 180 patients will be randomized in a 1:1 ratio. The primary endpoint is progression-free survival (PFS) assessed by an Independent Review Committee (IRC). The key secondary endpoint is overall survival (OS). The study is being conducted at approximately 40 to 60 centers across China.
Conditions
- PTCL
- NK T-Cell Lymphoma
Interventions
TR115Drug
TR115 will be administered orally twice daily until documented disease progression, unacceptable toxicity, withdrawal of consent, death, or study discontinuation.
Investigator's ChoiceDrug
Investigator's choice treatment with chidamide, golidocitinib, mitoxantrone hydrochloride liposome, or gemcitabine hydrochloride administered according to the respective approved prescribing information.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From randomization to disease progression or death from any cause, whichever occurs first, assessed up to 36 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijin, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.